Research roundup: diagnostic and prognostic cancer markers
Interested in seeing more of our cancer research antibodies in action? The following three studies have successfully utilized different Atlas Antibodies products to suggest or identify new biomarkers for different cancers.
1. IgG Fc binding protein (FCGBP) is downregulated in metastatic lesions and predicts survival in metastatic colorectal cancer patients (Yuan et al. 2021)
In metastatic colorectal cancer, resistance to chemotherapy limits treatment efficacy due to individual differences and drug targets. This discovers additional clinical biomarkers important to improve prognosis and find alternative clinical options. In this study, IgG-binding protein and colorectal cancer biomarker FCGBP are shown to be downregulated with disease progression. Additionally, the authors observed the relationship between FCGBP expression and the clinical features of liver metastases of colorectal cancer, showing a connection with better outcomes for patients with liver metastasis.
Fig. 1 Atlas Antibodies image of immunohistochemical analysis in the human small intestine and liver tissues using the anti-FCGBP antibody (HPA003564). Corresponding FCGBP RNA-seq data are presented for the same tissues.
- This study utilized our anti-FCGBP polyclonal antibody (HPA003564) for IHC on FFPE-processed human tumor tissues.
Take a look at our post "5 tips about validation when choosing an antibody" where we talk about the approved international guidelines for antibody validation.
2. Soluble protein tyrosine phosphatase receptor type Z (PTPRZ) in cerebrospinal fluid is a potential diagnostic marker for glioma (Yamanoi et al. 2020)
Non-invasive imaging of brain tumors like malignant glioma has limited diagnostic strength. This means that biopsies, which can cause harm and adverse events, often need to be taken. An alternative route could be to measure the presence of critical biomarkers in cerebrospinal fluid (CSF).
Fig. 2 Atlas Antibodies image of immunohistochemical analysis of the human cerebral cortex and liver tissues using the anti-PTPRZ1 antibody (HPA015103). Corresponding PTPRZ1 RNA-seq data are presented for the same tissues.
CSF sampling represents a largely non-invasive method that, together with non-invasive imaging, could provide accurate information about the tumor being investigated. In this paper, the authors identify soluble PTPRZ (phosphacan) as a promising marker for malignant glioma. If this finding can be replicated, soluble PTPRZ can be added to the shortlist of tumor markers measurable in the cerebrospinal fluid of patients with glioma.
This study used our anti-PTPRZ polyclonal antibody (HPA015103) for IHC on FFPE glioma tissue.
3. Sirtuin1 expression and survival in endometrial and clear-cell uterine cancer (Beyer et al. 2020)
The aim of the study was to evaluate the prognostic value of the histone deacetylase sirtuin- (SIRT1) in endometrioid and clear-cell cancer of the uterus. Most previous studies have only addressed the fact that SIRT1 is overexpressed in endometrial and endothelial ovarian cancer types.
The most important finding by the authors of this paper is that SIRT was significantly higher in endometroid carcinoma than in uterine clear cell carcinoma.
Fig. 3 Image from the study. Sirtuin1 expression in endometrioid uterine carcinoma with an IRS score of 4. examples for Sirtuin1 positives cells are marked by →. Scale bar 200 µm, small pictures 100 µm
The results show that SIRT1 predicts better overall survival in endometroid cancer of the uterus than in patients lacking SIRT1. Progression-free survival was better in uterine endometrioid, and clear-cell carcinoma for patients with SIRT1 expressed.
This study is the first to report a correlation between SIRT1 and survival in uterine cancer. Further studies are necessary to elucidate the role of SIRT1 in uterine and ovarian cancer and its potential as a therapeutic target.
This study used our anti SIRT1 polyclonal antibody (HPA006295) on the tissue microarray of endometrioid uterine carcinoma.